Showing results (141-150 of 264) with videos related to

Sort By:
Pageof 27
Annals of Hematology|July 21, 2017
Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabineJae-Cheol Jo, Dok Hyun Yoon, Shin Kim, et al.
Investigational New Drugs|March 10, 2018
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapyHyungwoo Cho, Dok Hyun Yoon, Kyu-Pyo Kim, et al.
Leukemia & Lymphoma|April 16, 2020
The clinical outcomes of rituximab biosimilar CT-P10 (Truxima®) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experienceKyoungmin Lee, Joo Young Ha, Ah Ra Jung, et al.
Immune Network|November 12, 2015
Engagement of CD99 Reduces AP-1 Activity by Inducing BATF in the Human Multiple Myeloma Cell Line RPMI8226Minchan Gil, Hyo-Kyung Pak, Seo-Jeong Park, et al.
Investigational New Drugs|December 31, 2009
A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunctionDok Hyun Yoon, Hyo Jung Lee, Yong Sang Hong, et al.
International Journal of Oncology|May 4, 2012
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1Yong Sang Hong, Seung-Woo Hong, Seung-Mi Kim, et al.
Oncotarget|September 24, 2017
The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myelomaJin Roh, Youkyoung Jeon, A-Neum Lee, et al.
Cancers|August 13, 2020
First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 TrialHo-Young Yhim, Dok Hyun Yoon, Seok Jin Kim, et al.
Japanese Journal of Clinical Oncology|May 25, 2010
Sorafenib for recurrent hepatocellular carcinoma after liver transplantationDok Hyun Yoon, Baek-Yeol Ryoo, Min-Hee Ryu, et al.
Cancer Research and Treatment|July 31, 2025
Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in KoreaJun Ho Yi, Jae Hoon Lee, Sung-Hoon Jung, et al.
Pageof 27